Handok acquired a domestic item license for paroxysmal nocturnal hemoglobinuria (PNH) treatment 'Ultomiris'. Ultomiris is a product that was expected as a successor to Soliris, and is a drug developed by Alexion, like Soliris.

In particular, it has attracted attention in that it has increased convenience by significantly reducing the number of doses than Soliris.

On the 21st, the MFDS approved a license for Ultomiris (Ravulizumab) by Handok as a treatment for paroxysmal nocturnal hemoglobinuria (PNH) in adults on the 21st.

Ultomiris is a drug approved by the U.S. Food and Drug Administration (FDA) in December 2018 and the European Medicines Agency (EMA) in July 2018. In Kor